Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy

• Published in: Blood Vol. 142; no. 25; pp. 2192 - 2197
• Main Authors: Pagani, Ilaria S, Shanmuganathan, Naranie, Dang, Phuong, Saunders, Verity A, Grose, Randall, Kok, Chung H, James, Jane, Tolland, Molly, Braley, Jodi A, Altamura, Haley K, Yeung, David T, Branford, Susan, Yong, Agnes S M, Hughes, Timothy P, Ross, David M
• Format: Journal Article
• Language: English
• Published: United States 21.12.2023
• Subjects: DNA; Fusion Proteins, bcr-abl - genetics; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Protein Kinase Inhibitors; Recurrence; Remission Induction
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.2023021119

Patients with chronic myeloid leukemia who are eligible for treatment-free remission (TFR) may still relapse after tyrosine kinase inhibitor (TKI) cessation. There is a need for accurate predictors of outcome to enable patients with a favorable profile to proceed while avoiding futile attempts. Sensitive detection of residual disease in total leukocytes at treatment cessation is associated with relapse but is not highly discriminatory, likely because it is a composite measure of residual leukemia derived from different cell lineages, whereas only some lineages are relevant for relapse. We prospectively measured BCR::ABL1 DNA as a predictive yes/no binary test in 5 cellular fractions from 48 patients meeting conventional criteria for TKI discontinuation. The median BCR::ABL1 DNA level was higher in granulocytes and T cells, but not in other lineages, in patients who relapsed. Among the 40 patients undergoing their first TFR attempt, we defined 3 groups with differing relapse risk: granulocyte-positive group (100%), granulocyte-negative/T-cell-positive group (67%), and granulocyte-negative /T-cell-negative group (25%). These data show the critical importance of lineage-specific assessment of residual disease in the selection of patients who can attempt to achieve TFR with a high expectation of success and, concurrently, defer patients who have a high probability of relapse.